Studies on hypoxia-signaling pathways have revealed novel Fe(lI) and a-ketoglutarate-dependent dioxygenases that hydroxylate prolyl or asparaginyl residues of a transactivator, Hypoxia-Inducible Factor-a (HIF-a) protein. The recognition of these unprecedented dioxygenases has led to open a new paradigm that the hydroxylation mediates an instant post-translational modification of a protein in response to the changes in cellular concentrations of oxygen, reducing agents, or a-ketoglutarate. Activity of HIF-a is repressed by two hydroxylases. One is HIF-a specific prolyl-hydroxylases, referred as prolyl-hydroxylase domain (PHD). The other is HIF-a specific asparaginyl-hydroxylase, referred as factor-inhibiting HIF-1 (FIH-1). The facts (i) that many dioxygenases commonly use molecular oxygen and reducing agents during detoxification of xenobiotics, (ii) that detoxification reaction produces radicals and reactive oxygen species, and (iii) that activities of both PHD and FIH-1 are regulated by the changes in the balance between oxygen species and reducing agents, imply the possibility that the activity of HIF-a can be increased during detoxification process. The importance of HIF-a in cancer and ischemic diseases has been emphasized since its target genes mediate various hypoxic responses including angiogenesis, erythropoiesis, glycolysis, pH balance, metastasis, invasion and cell survival. Therefore, activators of PHDs and FIH-1 can be potential anticancer drugs which could reduce the activity of HIF, whereas inhibitors, for preventing ischemic diseases. This review highlights these novel dioxygenases, PHDs and FIH-1 as specific target against not only cancers but also ischemic diseases.
(bHLH-PAS) proteins, including Period (Per), aryl hydrocarbon receptor nuclear translocator (Arnt) and Singleminded (Sim) (Fig. 2) . The bHLH-PAS proteins share common characteristics; first, a bHLH-PAS protein dimerizes with a specific partner protein through the HLH-PAS domain. Second, aryl hydrocarbon receptor (AhR) or HIF-1a is activated by specific stimuli i.e., xenobiotics or low oxygen tension, respectively, before translocating to the nucleus where it heterodimerizes with a partner protein. Alternatively, Arnt, another bHLH-PAS protein, is constitutively located in the nucleus and interacts with several bHLH-PAS proteins in diverse pathways. Amt, identical to HI F-1 ~, is known to be a common partner protein of AhR, mouse single-minded (mSim) and HIF-1 a. Third, interactions between HLH-PAS domains bring two basic regions of the two subunits into juxtaposition, enabling individual basic regions to contact specific corresponding DNA sequences. Thus, dimerization of bHLH-PAS proteins is a prerequisite for DNA binding (Crews, 1998) . HIF-1 a was the original HIF-a isoform identified by affinity purification, while HIF-2a was identified in a homology search (Tian et al., 1998) . Both HIF-1a and HIF-2a form functional heterodimers with Arnt. HIF-1a protein is rapidly accumulated in acute hypoxia, and then declines after prolonged hypoxia, whereas HIF-2a protein increases slowly but continuously in prolonged hypoxia (Holmquist-Mengelbier et a/., 2006).
Oxygen-dependent regulation of HIF-1 a. Exposure to hypoxia for less than 2 min already revealed nuclear HIF-1a protein. One hour after hypoxic exposure, nuclear HIF-1a proteins reached maximal levels. HIF-1 a induction is very instant in response to oxygen level (Jawell, et al., 2001) . In normoxia, HIF-1 a is ubiquitinated and rapidly degraded while HIF-1 ~ (Amt) is constitutively expressed. The stability and activity of the a subunit of HIF-1 are regulated by posttranslational modification, specifically, by hydroxylation. Proline residues 402 and 564 of the oxygen-dependent degradation domain (ODD, amino acids 401-603 of human HIF-1a) are hydroxylated, mainly by HIF-1 a-specific proly-4-hydroxylase (PHD) using molecular oxygen, a-ketoglutarate, vitamin C (Vit. C), and Fe(lI) (Eptein et al., 2001) . The hydroxylated prolines are recognized by the E3 Hypoxia ubiquitin ligase, von Hippel-Lindau protein (pVHL), following which HIF-1a is polyubiquitinated and degraded by the 26S proteasomal system . Hypoxia-induced trans-activation ability of HIF-1a is regulated by different mechanisms than its stabilization. To be a functional transactivator, the stabilized HIF-1a should be able to recruit its coactivator, CBP/p300. Asparagine 803 of human HIF-1a is also hydroxylated under normoxic conditions by an oxygen-dependent asparagine hydroxylase, referred to as Factor-Inhibiting HIF-1 (FIH-1). The hydroxylated asparagine residue hinders the recruitment of CBP/p300, thereby inhibiting transactivation by the stabilized HIF-1a (Fig. 3) . A lack of oxygen reduces the activities of these two oxygendependent hydroxylases, so stabilizing the transactive form of HIF-1a Lando et al., 2002) . The findings of PHD and FIH-1 explain how HIF-1 a is instantly activated with a few minutes in response to hypoxia. Therefore these dioxygenases are the ultimate O 2 sensors for hypoxic induction of genes.
PHDs and FIH-1. By using a genetic approach in the roundworm C. elegans, Epstein et al. (2001) identified VHL and HIF-1a homologs. The investigators searched the C. elegans genome database for sequences that might encode a member of the a-ketoglutarate-dependent oxygenase superfamily and identified egl-9 gene, which stimulates the interaction between VHL and HIF-1a. Using the egl-9 sequences, three mammalian homologs of egl-9 were identified, and referred as PHD 1, 2 and 3. By using siRNA against PHD1, 2 or 3, PHD2 is found to be the major HIF-1a prolyl-4-hydroxylase (Berra et al., 2003) . PHD2 shares the conserved catalytic domain of a-ketoglutarate-dependent dioxygenases with other prolyl-4 hydroxylases including PHD1, PHD3 and collagen prolyl hydroxylase, but has a unique N-terminal MYND-type zinc finger domain which inhibits the catalytic activity of PHD2 (Choi et al., 2005) .
FIH-1 has been identified as a protein that interacts with both HIF-1a and VHL, and that inhibits transactivation function of HIF-1a (Mahon et al., 2001) . Later, Lando et al. (2002) first found that FIH-1 is an asparaginyl hydroxylase. Asparagine-B03 in the C-terminal transactivation domain of HIF-1a is hydroxylated by FIH-1 under normoxic conditions causing abrogation of the HIF-1a1p300 interaction McNeill et al., 2002) . Both PHDs and FIH-1 belong to the family of a-ketoglutarate-dependent dioxygenases, which also require 02' Fe(II), and Vit. C for their reaction (Fig. 4) .
The structure of FIH-1 is distinct from those of PHDs and collagen-prolyl-4-hydroxylase. The catalytic region of FIH-1 (145 to 340 amino acids of human FIH-1) belongs to the Jumonji (Jmj) domain which is often found in histone demethylases (Lee et al., 2003; Klose et al., 2006; Ng et al., 2007) . Jmj domains catalyze the oxidative demethylation of a methylated lysine residue of histone (Fig. 5) . Although Jmj domain and FIH-1 hydroxylate different target proteins, both commonly utilize 02, a-ketoglutarate, Vit. C and Fe(ll) and produce succinate and CO2, Both PHDs and FIH-1 hydroxylates HIF-a by using common cofactors, however FIH-1 has unique features in terms of structure and catalytic properties compared to PHDs (Hewitson et al., 2007; Koivunen et aI., 2007) . 1C4H, collagen prolyl-4-hydroxylase
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Lysine indicating that minor decease in oxygen effectively represses the activity of PHDs (Hirsila et al., 2003) . In contrast, the Km values of FIH-1 and collagen prolyl-4 hydroxylase (C4H) for O2 are 90 flM and 40 ~lM respectively, indicating that catalytic activities of FIH-1 and collagen prolyl-4 hydroxylase become half of maximum activity at 4.25% and 2% oxygen tension, respectively (Koivunen et al., 2004; Vuorela et a/., 1997) . Therefore, a larger decrease in O2 concentration is required for a significant reduction in the activity of FIH-1, thus leading to full transactivation of HIF-1a (Koivunen et a/., 2007) . Recent findings showed that differently from the cultured cells, O 2 concentration of mammalian tissue in a body is estimated about 2 to 10% oxygen tension, suggesting that the activities of both PHDs and FIH-1 are limited in a tissue (Brahimi-Horn and Pouyssegur 2007) . Therefore, in a normal tissue the basal level of HIF-1a may be higher than that of the cultured cells in 20% oxygen tension. The fact that the catalytic activities of both PHDs and FIH-1 are related with the concentration of not only O2 but also other co-substrates including a-ketoglutarate, Fe(ll) and Vit. C, suggests that beside of hypoxia, any cellular events that cause the decrease in these co-substrates inhibits the activities of both PHDs and FIH-1. The Km values of PHDs for a-ketoglutarate are about two fold higher than those of FIH-1 and collagen prolyl-4 hydroxylase, indicating that they may show the distinct difference in their response to competitive inhibitors (Hewitson et al., 2007; Hirsila et al., 2005; Nangaku et al., 2006 , Nytko et a/., 2007 . Succinate and fumarate inhibit PHD but not FIH-1 activity (Hewitson et al., 2007; Koivunen et a/., 2007) . Desferrioxamine and several metals are effective inhibitors of FIH-1 but ineffective inhibitors of PHDs in vitro (Hirsila et al., 2005) .
Activators of PHD2 and FIH-1 as anticancer drugs.
Tumors are frequently hypoxic due to the lack of blood supply and high oxygen consumption. Consequently, HIF is activated in most of cancers and contributes to survival and progression of cancers by triggering angiogenesis, glycolysis, H+ export and metastasis (Esteban and Maxwell, 2005; Esteban et al., 2006; Isaacs et al., 2005; Koike et al., 2004; Pouyssegur et a/., 2006) . Activators of PHDs and FIH-1 can be potential anticancer drugs which could reduce the activity of HIF (Choi et al., 2008; Ginouves et al., 2008; Shin et al., 2007 Shin et al., , 2008 . Inherited genetic defects in either fumarate hydratase (Selak et al., 2005) or succinate dehydrogenase (Pollard et al., 2005) cause tumor, however the mechanism of this cancer syndrome has not been known. The finding of PHD gave an answer. During dioxygenation reaction, PHDs catalyses HIF-a hydroxylation using a-ketoglutarate and generate succinate as a product. Loss-of-function mutations in fumarate hydratase or succinate dehydrogenase lead to the increase levels of succinate and fumarate. Then the excess succinate and fumarate could antagonize PHDs, leading to activation of HIF-a.
PHDs and FIH-1 also utilize Vit. C for their hydroxylation reaction. Vit. C and Vit. E are the major antioxidants which scavenge radicals such as reactive oxygen species. Anticancer activity of Vit. C has been presumed to arise from its ability to scavenge reactive oxygen species which cause DNA damage. Gao et al. (2007) showed that ectopic expression of stabilized HIF-1 mutant rescued the tumor from inhibition by Vit. C, indicating that Vit. C suppresses tumorigenesis primarily by activating PHDs rather than deceasing DNA damage.
Inhibitors of PHDs and FIH-1, for ischemic diseases. HIF-1 attenuates ischemic injury. The beneficial effects of HIF-1 are mostly mediated by its target genes, the most prominent of which are EPO and VEGF, which are considered major mediators of the protective effect of hypoxic preconditioning (Baranova et al., 2007; Grimm et al., 2002; Natarajan et al., 2006) . Therefore, inhibitors of both PHDs and FIH-1 can be useful as an inducer of HIF-a and its target genes in ischemic diseases such as myocardial or cerebral infarction. Choi et al. (2006) found that the Cu(lI) and Zn(II)-specific chelator Clioquinol (10-50 ~lM) increases functional HIF-1 a protein, leading to increased expression of its target genes, VEGF and EPO. Interestingly, Clioquinol prevents FIH-1 from hydroxylating the asparagines residue (803), Cu(II)-and Zn(II)-independently. In contrast, Clioquinol fails to prevent PHD2 from hydroxylating proline. Instead, it blocks ubiquitination of the proline-hydroxylated HIF-1a in Cu(II)-and Zn(II)-dependent manner, thereby clioquinol stabilizes the trans-active form of HIF-1a (Choi et al., 2006) .
The mechanisms by which NO donors activate the function of HIF-1a are very diverse (BrOne and Zhou, 2007) . NOC18 stimulates translation of HIF-1 a by activating the PI3 kinase and Akt pathways (Kasuno et al., 2004) . Park et al. (2008) demonstrated that NO donor, SNAP inhibits FIH-1 but not PHD2. Instead, it inhibits VHL recruitment, through S-nitrosylation of ODD. Thus SNAP stabilizes the trans-active form of HIF-1a in normoxic cells. Interestingly, these inhibitory effects of SNAP can be reversed by addition of reducing agents such as excess Vit. C or Fe(lI) indicating that cellular redox status affects SNAP action, presumably NO release from SNAP. Consistently, Li et al. (2007) demonstrated, using an antibody directed against the hydroxylated proline of HIF-1a, that in GSNO-treated mouse 4T tumor cells, proline-hydroxylated HIF-1a remained detectable. Biotin switch assay showed that a cysteine residue of ODD domain is nitrosylated, and that this S-nitrosylation does not inhibit proline hydroxylation but blocks VHL recruitment.
Other substrates of PHDs and FIH-1. The findings of PHDs and FIH-1 have raised a question whether these hydroxylases have alternative substrates. Other substrates for PHD2 have not been found yet. However, Poellinger's group showed that FIH-1 hydroxylates Notch at two residues (N 1945 and N 2012 ) (Zheng et al., 2008) . In a screen for proteins interacting with FIH-1, Ratcliffe's group also has show that FIH-1 also efficiently hydroxylates specific asparaginyl (Asn)-residues of other ankyrin repeat domain-containing proteins such as NFKB and IKBa (Cockman et al., 2006) . These findings demonstrate that this type of protein hydroxylation is not restricted to HIF and strongly suggest that FIHdependent ankyrin repeat domain (ARD) hydroxylation is a common occurrence, potentially providing an oxygen-sensitive signal to a diverse range of processes.
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